Barclays’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Barclays’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,710	Closed	-$7K	–	5417
2022 Q1	$7K	Buy	+11,710	New	+$6.14K	﹤0.01%	4667

Other funds holding MTCR

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Barclays's MTCR Position: Q2 2022 in Review

Barclays sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2022, closing a stake of 11,710 shares — an estimated $7K sold.

Barclays first reported a position in MTCR in Q1 2022 and held it in 1 quarter. The position peaked at $7K in Q1 2022. 25 funds tracked by Wall St. Rank hold MTCR as of Q2 2022.

Barclays reported no remaining Metacrine, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Barclays sold 11,710 Metacrine, Inc. Common Stock shares in Q2 2022, an estimated $7K.
Barclays first reported a position in Metacrine, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
Barclays's Metacrine, Inc. Common Stock position peaked at $7K in Q1 2022.
25 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.